

Giusy Elia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5879561/publications.pdf>

Version: 2024-02-01

59
papers

2,007
citations

304743

22
h-index

276875

41
g-index

59
all docs

59
docs citations

59
times ranked

2047
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular targets of tyrosine kinase inhibitors in thyroid cancer. <i>Seminars in Cancer Biology</i> , 2022, 79, 180-196.	9.6	64
2	Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin. <i>Seminars in Cancer Biology</i> , 2022, 79, 203-216.	9.6	12
3	Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 599-610.	1.8	5
4	Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5731.	4.1	9
5	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	1.9	7
6	Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases. <i>Journal of Autoimmunity</i> , 2022, 131, 102866.	6.5	10
7	THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors. <i>European Journal of Endocrinology</i> , 2021, 184, R29-R40.	3.7	20
8	L-T4 Therapy in Enteric Malabsorptive Disorders. <i>Frontiers in Endocrinology</i> , 2021, 12, 626371.	3.5	13
9	COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. <i>Lancet Rheumatology</i> , The, 2021, 3, e166-e168.	3.9	25
10	The Stability of TSH, and Thyroid Hormones, in Patients Treated With Tablet, or Liquid Levo-Thyroxine. <i>Frontiers in Endocrinology</i> , 2021, 12, 633587.	3.5	10
11	Cytokines as Targets of Novel Therapies for Gravesâ€™ Ophthalmopathy. <i>Frontiers in Endocrinology</i> , 2021, 12, 654473.	3.5	24
12	The Synergistic Effect of Corticosteroids and Mycophenolic Acid on Chemokines in Orbital Cells From Patients With Gravesâ€™ Ophthalmopathy. <i>Journal of the Endocrine Society</i> , 2021, 5, A845-A846.	0.2	0
13	Serum TSH Levels Normalisation in Patients Affected by Autoimmune Atrophic Gastritis, After the Switch From Oral L-T4 in Tablet Form to L-T4 in Liquid Formulation. <i>Journal of the Endocrine Society</i> , 2021, 5, A833-A833.	0.2	0
14	Oral Liquid L-Thyroxine (L-T4) May Be Better Absorbed in Comparison to L-T4 Tablets in Patients With Lactose Intolerance. <i>Journal of the Endocrine Society</i> , 2021, 5, A832-A832.	0.2	1
15	Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 913-921.	4.1	3
16	Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. <i>Current Pharmaceutical Design</i> , 2021, 27, 4245-4252.	1.9	12
17	Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases. <i>Lancet Rheumatology</i> , The, 2021, 3, e675-e676.	3.9	10
18	Precision Medicine in Gravesâ€™ Disease and Ophthalmopathy. <i>Frontiers in Pharmacology</i> , 2021, 12, 754386.	3.5	13

#	ARTICLE	IF	CITATIONS
19	Precision Medicine in Autoimmune Thyroiditis and Hypothyroidism. <i>Frontiers in Pharmacology</i> , 2021, 12, 750380.	3.5	11
20	Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patientsâ€™ subgroups. <i>Journal of Autoimmunity</i> , 2021, 125, 102744.	6.5	83
21	Thyroid autoimmune disorders and cancer. <i>Seminars in Cancer Biology</i> , 2020, 64, 135-146.	9.6	100
22	New insight in endocrine-related adverse events associated to immune checkpoint blockade. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101370.	4.7	60
23	Novel therapies for thyroid autoimmune diseases: An update. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101366.	4.7	26
24	Th1 Chemokines in Autoimmune Endocrine Disorders. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1046-1060.	3.6	56
25	The Covid-19, Epidemiology, Clinic and Prevention. <i>Current Genomics</i> , 2020, 21, 157-160.	1.6	7
26	Nutraceuticals in Thyroidology: A Review of in Vitro, and in Vivo Animal Studies. <i>Nutrients</i> , 2020, 12, 1337.	4.1	19
27	Gravesâ€™ disease: Epidemiology, genetic and environmental risk factors and viruses. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101387.	4.7	120
28	Endocrine disruptors and thyroid autoimmunity. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101377.	4.7	43
29	Novel treatments for anaplastic thyroid carcinoma. <i>Gland Surgery</i> , 2020, 9, S28-S42.	1.1	69
30	Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101388.	4.7	72
31	Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up. <i>Gland Surgery</i> , 2019, 8, 298-300.	1.1	8
32	<p>Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7893-7907.	1.9	14
33	Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?. <i>Journal of Immunology Research</i> , 2019, 2019, 1-11.	2.2	24
34	Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4413.	4.1	140
35	Recent advances in precision medicine for the treatment of anaplastic thyroid cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 37-49.	0.7	3
36	Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2560.	4.1	72

#	ARTICLE	IF	CITATIONS
37	Chemokines in hyperthyroidism. <i>Journal of Clinical and Translational Endocrinology</i> , 2019, 16, 100196.	1.4	25
38	The aggregation between AITD with rheumatologic, or dermatologic, autoimmune diseases. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2019, 33, 101372.	4.7	16
39	Hashimotosâ€™™ thyroiditis: Epidemiology, pathogenesis, clinic and therapy. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2019, 33, 101367.	4.7	251
40	The association of other autoimmune diseases in patients with Graves' disease (with or without) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 287-292.	5.8	91
41	MON-566 Early Diagnosis of Lymph Node Metastases by Serum Tg and Neck Ultrasonography, and Long Term Follow Up After Radioiodine and/or Surgical Treatment in Patients with Papillary or Follicular Thyroid Cancer.. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
42	MON-594 Report Of A Large Series Of Patients With Graves' Disease (with/without Graves') Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 547 T Diseases. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
43	MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
44	MON-LB102 Liquid L-Thyroxine Can Maintain Stable TSH Values in Patients with Hypothyroidism: A Prospective Study. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
45	Differential modulation by vanadium pentoxide of the secretion of CXCL8 and CXCL11 chemokines in thyroid cells. <i>Molecular Medicine Reports</i> , 2018, 17, 7415-7420.	2.4	5
46	The paramount role of cytokines and chemokines in papillary thyroid cancer: a review and experimental results. <i>Immunologic Research</i> , 2018, 66, 710-722.	2.9	11
47	Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration. <i>Frontiers in Endocrinology</i> , 2018, 9, 764.	3.5	19
48	Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. <i>Oncology Reports</i> , 2018, 39, 2306-2314.	2.6	21
49	Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. <i>Oncology Reports</i> , 2018, 39, 2225-2234.	2.6	38
50	The protective effect of myo-inositol on human thyrocytes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018, 19, 355-362.	5.7	11
51	Myo-inositol in autoimmune thyroiditis, and hypothyroidism. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018, 19, 349-354.	5.7	28
52	Molecular testing in the diagnosis of differentiated thyroid carcinomas. <i>Gland Surgery</i> , 2018, 7, S19-S29.	1.1	44
53	CCL2 is Modulated by Cytokines and PPAR-Î³ in Anaplastic Thyroid Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 458-466.	1.7	14
54	Increased incidence of autoimmune thyroid disorders in patients with psoriatic arthritis: a longitudinal follow-up study. <i>Immunologic Research</i> , 2017, 65, 681-686.	2.9	28

#	ARTICLE	IF	CITATIONS
55	Novel treatment options for anaplastic thyroid cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2017, 12, 279-288.	2.4	13
56	Systemic Lupus Erythematosus and Thyroid Autoimmunity. <i>Frontiers in Endocrinology</i> , 2017, 8, 138.	3.5	34
57	The association of other autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and report of a large series of patients. <i>Autoimmunity Reviews</i> , 2016, 15, 1125-1128.	5.8	155
58	Incidence of thyroid disorders in mixed cryoglobulinemia: Results from a longitudinal follow-up. <i>Autoimmunity Reviews</i> , 2016, 15, 747-751.	5.8	13
59	Novel Therapies for Thyroid Autoimmune Diseases. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 853-861.	3.1	25